Other equities research analysts have also recently issued reports about the stock. ValuEngine upgraded shares of Achillion Pharmaceuticals from a sell rating to a hold rating in a research report on Wednesday, October 16th. JMP Securities lowered shares of Achillion Pharmaceuticals from an outperform rating to a market perform rating in a research note on Thursday, November 7th. Svb Leerink lowered shares of Achillion Pharmaceuticals from an outperform rating to a market perform rating and increased their target price for the stock from $5.00 to $6.30 in a research note on Friday, October 18th. Finally, Leerink Swann lowered shares of Achillion Pharmaceuticals from an outperform rating to a market perform rating and set a $6.30 target price for the company. in a research note on Friday, October 18th. Two analysts have rated the stock with a sell rating, five have issued a hold rating and one has assigned a buy rating to the company’s stock. The company currently has an average rating of Hold and a consensus price target of $4.96.
NASDAQ:ACHN opened at $6.19 on Friday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.96 and a current ratio of 8.96. The company has a fifty day moving average of $6.15 and a two-hundred day moving average of $4.98. The stock has a market capitalization of $866.91 million, a PE ratio of -11.46 and a beta of 1.59. Achillion Pharmaceuticals has a fifty-two week low of $2.06 and a fifty-two week high of $6.46.
In other Achillion Pharmaceuticals news, Director David Scheer sold 10,485 shares of the stock in a transaction dated Wednesday, November 13th. The shares were sold at an average price of $6.31, for a total transaction of $66,160.35. Following the completion of the transaction, the director now owns 40,000 shares of the company’s stock, valued at $252,400. The sale was disclosed in a legal filing with the SEC, which is available at this link. Company insiders own 4.58% of the company’s stock.
Hedge funds and other institutional investors have recently bought and sold shares of the company. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in shares of Achillion Pharmaceuticals by 142.5% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,227 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 4,247 shares during the period. Bank of Montreal Can acquired a new stake in Achillion Pharmaceuticals in the second quarter valued at approximately $30,000. Meeder Asset Management Inc. raised its holdings in Achillion Pharmaceuticals by 677.1% in the third quarter. Meeder Asset Management Inc. now owns 19,551 shares of the biopharmaceutical company’s stock valued at $70,000 after acquiring an additional 17,035 shares in the last quarter. Bourgeon Capital Management LLC acquired a new stake in Achillion Pharmaceuticals in the third quarter valued at approximately $72,000. Finally, Paloma Partners Management Co acquired a new stake in Achillion Pharmaceuticals in the second quarter valued at approximately $74,000. 79.81% of the stock is owned by institutional investors and hedge funds.
About Achillion Pharmaceuticals
Achillion Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for immune system disorders. Its lead drug candidate is ACH-4471, an inhibitor of factor D that is Phase II clinical trials for patients with paroxysmal nocturnal hemoglobinuria (PNH) and C3 glomerulopathy/immune complex membranoproliferative glomerulonephritis.
Recommended Story: How can investors invest in the S&P/TSX Index?
Receive News & Ratings for Achillion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.